Literature DB >> 30368725

Antigen-loaded dendritic cells triggers a specific cytotoxic T lymphocytes immune response against hepatocellular carcinoma: in vitro study.

N E El-Ashmawy1, E A El-Zamarany2, E G Khedr1, H A El-Bahrawy1, O A El-Feky3.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the common malignancies, characterized by poor response to conventional therapeutic options. Immunotherapy with dendritic cells (DCs)-vaccines is one of the most successful strategies used for the treatment of HCC. However, the methods applied in the preparation of antigen-loaded DCs are important factors for optimization of DCs vaccines.
PURPOSE: The present study was conducted to investigate the effect of HCC-whole tumor cell lysate prepared using rapid repetitive freeze-thaw cycles on the immunogenicity of DCs and evaluate the ability of whole tumor cell lysate-pulsed DCs vaccine to induce a specific cytotoxic T lymphocytes (CTLs) response against HepG2 cell line.
METHODS: Immature DCs generated from peripheral blood monocytes were randomized into two groups: control DCs and whole tumor cell lysate-pulsed DCs. Phenotypic analysis of the DCs' cell maturation marker CD83 and co-stimulatory molecule CD86 was performed. HCC-specific cytotoxic activity of CD8+ CTLs was measured in vitro.
RESULTS: Loading of DCs with necrotic whole cell lysate resulted in non-significant changes in DCs' expression of CD83, but a significant increase in expression of CD86. In addition, CD8+ CTLs stimulated with whole tumor cell lysate-pulsed DCs showed a high cytotoxic activity that specifically attack HepG2 cells.
CONCLUSION: Our findings indicated that pulsation of DCs with whole tumor cell lysate prepared by repetitive freeze-thaw cycles could efficiently enhance the ability of DCs to induce proliferation and clonal expansion of CD8+ CTLs. Data herein, also indicated that whole tumor cell lysate-pulsed DCs triggers a specific CD8+ CTLs against HCC tumor cells.

Entities:  

Keywords:  CD8 cell; Cell immunotherapy; Dendritic cells; Hepatocellular carcinoma

Mesh:

Substances:

Year:  2018        PMID: 30368725     DOI: 10.1007/s12094-018-1965-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  29 in total

1.  Immunotherapy synergizes with chemotherapy targeting pancreatic cancer.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Hideo Komita; Kan Uchiyama; Masaki Ito; Jianlin Gong; Toshifumi Ohkusa; Hisao Tajiri
Journal:  Immunotherapy       Date:  2012-01       Impact factor: 4.196

2.  Antigen-bearing dendritic cells regulate the diverse pattern of memory CD8 T-cell development in different tissues.

Authors:  Ching-Hung Shen; Oezcan Talay; Vinay S Mahajan; Ilya B Leskov; Herman N Eisen; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

Review 3.  Manipulating immune cells for adoptive immunotherapy of cancer.

Authors:  Phillip K Darcy; Paul Neeson; Carmen S M Yong; Michael H Kershaw
Journal:  Curr Opin Immunol       Date:  2014-02-15       Impact factor: 7.486

4.  Antigen availability determines CD8⁺ T cell-dendritic cell interaction kinetics and memory fate decisions.

Authors:  Sarah E Henrickson; Mario Perro; Scott M Loughhead; Balimkiz Senman; Susanne Stutte; Michael Quigley; Gabriela Alexe; Matteo Iannacone; Michael P Flynn; Shaida Omid; Jonathan L Jesneck; Sabrina Imam; Thorsten R Mempel; Irina B Mazo; W Nicholas Haining; Ulrich H von Andrian
Journal:  Immunity       Date:  2013-09-19       Impact factor: 31.745

5.  Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.

Authors:  Akitaka Takahara; Shigeo Koido; Masaki Ito; Eijiro Nagasaki; Yukiko Sagawa; Takeo Iwamoto; Hideo Komita; Toshiki Ochi; Hiroshi Fujiwara; Masaki Yasukawa; Junichi Mineno; Hiroshi Shiku; Sumiyuki Nishida; Haruo Sugiyama; Hisao Tajiri; Sadamu Homma
Journal:  Cancer Immunol Immunother       Date:  2011-05-24       Impact factor: 6.968

6.  CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.

Authors:  Alice W Yewdall; Scott B Drutman; Felecia Jinwala; Keith S Bahjat; Nina Bhardwaj
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

7.  Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.

Authors:  Da-Yong Cao; Jing-Yue Yang; Shu-Qiang Yue; Kai-Shan Tao; Zhen-Shun Song; De-Sheng Wang; Yan-Ling Yang; Ke-Feng Dou
Journal:  Cell Immunol       Date:  2009-05-27       Impact factor: 4.868

8.  Generation and function of induced regulatory T cells.

Authors:  Erica G Schmitt; Calvin B Williams
Journal:  Front Immunol       Date:  2013-06-19       Impact factor: 7.561

9.  Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.

Authors:  Tobias Flecken; Nathalie Schmidt; Sandra Hild; Emma Gostick; Oliver Drognitz; Robert Zeiser; Peter Schemmer; Helge Bruns; Thomas Eiermann; David A Price; Hubert E Blum; Christoph Neumann-Haefelin; Robert Thimme
Journal:  Hepatology       Date:  2014-02-20       Impact factor: 17.425

10.  Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients.

Authors:  D Reyes; L Salazar; E Espinoza; C Pereda; E Castellón; R Valdevenito; C Huidobro; M Inés Becker; A Lladser; M N López; F Salazar-Onfray
Journal:  Br J Cancer       Date:  2013-08-29       Impact factor: 7.640

View more
  2 in total

Review 1.  Chemically Engineered Immune Cell-Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools.

Authors:  Leila Pourtalebi Jahromi; Mohammad-Ali Shahbazi; Aziz Maleki; Amir Azadi; Hélder A Santos
Journal:  Adv Sci (Weinh)       Date:  2021-03-01       Impact factor: 16.806

Review 2.  Adipocyte-Based Cell Therapy in Oncology: The Role of Cancer-Associated Adipocytes and Their Reinterpretation as Delivery Platforms.

Authors:  Raluca Munteanu; Anca Onaciu; Cristian Moldovan; Alina-Andreea Zimta; Diana Gulei; Angelo V Paradiso; Vladimir Lazar; Ioana Berindan-Neagoe
Journal:  Pharmaceutics       Date:  2020-04-28       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.